Insider Selling: Spero Therapeutics, Inc. (NASDAQ:SPRO) Director Sells 69,219 Shares of Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO) Director Ankit Mahadevia sold 69,219 shares of Spero Therapeutics stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $0.78, for a total value of $53,990.82. Following the completion of the sale, the director now directly owns 689,866 shares of the company’s stock, valued at approximately $538,095.48. This trade represents a 9.12 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Spero Therapeutics Trading Down 5.2 %

SPRO stock opened at $0.82 on Friday. The firm has a 50 day moving average of $0.99 and a 200-day moving average of $1.19. The firm has a market capitalization of $44.62 million, a P/E ratio of 11.69 and a beta of 0.61. Spero Therapeutics, Inc. has a 12 month low of $0.74 and a 12 month high of $1.89.

Analysts Set New Price Targets

SPRO has been the subject of several recent research reports. Evercore ISI downgraded shares of Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 target price for the company. in a research note on Friday, December 20th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a research note on Friday, November 15th. TD Cowen restated a “hold” rating on shares of Spero Therapeutics in a research report on Monday, November 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Spero Therapeutics in a report on Thursday, January 30th.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.